Pancreatic cancer is globally one of the most common and most deadly cancers. There is therefore a tremendous need to find tools that can profile the drug sensitivity of each patient’s tumor. IndiTreat® has shown in colorectal as well as ovarian cancer that patients with seemingly similar tumor show very different drug responses. This heterogeneity opens new perspectives for personalized treatment. The clinical study has been approved by the Health Ethics Committee in Denmark.
"Cancer in the pancreas is one of the most serious cancer diseases, and therefore we need to improve our treatment," says Principal Investigator and Chief Oncologist Lars Henrik Jensen, University Hospital Vejle. He continues: "In the clinical trial we will clarify the ability of IndiTreat® to predict the efficacy and resistance of the medical treatments in incurable pancreatic cancer patients, and we aim at personalized, tailor-made treatment of each patient". Lars Henrik Jensen concludes: "In addition to finding the most effective life-prolonging treatment, there is also a very important perspective in identifying an effective neo-adjuvant treatment, which can down-stage the cancer, and thereby bringing more patients to surgery. It will increase the chance of survival. "
“Successful launch of this clinical validation trial is a key achievement for 2cureX since it opens up a new potential market for IndiTreat®” states the CEO of 2cureX, Ole Thastrup. He continues: “The pancreas trial has major perspectives for the patients inflicted with this devastating disease as well as for society in light of the globally growing number of elderly people thus reaching the “cancer age”. In addition, launching clinical trials in three major cancer entities within one year, is extremely exciting for 2cureX, and it underlines the general applicability of IndiTreat® to become an indispensable tool for oncologists to upfront define the drug sensitivity of each cancer patient’s tumor.”
IndiTreat® has been developed by 2cureX in its laboratory facilities in Copenhagen and in Hamburg.
Sedermera Fondkommission is the Certified Adviser of 2cureX.
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 15th, 2018.
For more information about 2cureX:
Ole Thastrup, CEO
Phone: +45 22 11 53 99
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented and CE-IVD marked test for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® presents the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal, ovarian and pancreatic cancer.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).